A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive
A phase 3 trial of Vebreltinib in non-small-cell lung cancer, run by Beijing Pearl Biotechnology Limited Liability Company, now recruiting.
Overview
A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive is a phase 3 interventional study registered as NCT06930794 by Beijing Pearl Biotechnology Limited Liability Company, with 300 participants planned, started 2025-07-07 and due to reach its primary completion in 2029-02. Interventions recorded: Vebreltinib combined with platinum-based doublet chemotherapy. and platinum-based doublet chemotherapy..
Similar pages
not linked directly; found by shared links- TrialA Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).
Shares Beijing Pearl Biotechnology Limited Liability Company, Vebreltinib.
- TrialA Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)
Shares Beijing Pearl Biotechnology Limited Liability Company, Vebreltinib, Non-small-cell lung cancer.
- TrialAllogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialStudy to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialA Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialPhase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialPhase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialFirst-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI
Shares Non-small-cell lung cancer and the tag pipeline.